For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

< Back to Agenda
Entering the MSC 2.0 Era: Building Blocks for Next Generation Therapies
Thursday, May 30, 2024 05:00 PM - 06:00 PM  
Room 211
Concurrent Session
Chair
  • Jon Rowley, PhD, RoosterBio, United States
Speakers
  • Gi-Hoon Nam, MD, PhD, SHIFTBIO Inc., Repulic of Korea, "Resolving Inflammation with High-Purity, Large-Scale Engineered Mesenchymal Stem Cell- Derived SIRPα Extracellular Vesicles through Necroptosis Clearance"
  • Sarindr "Ik" Bhumiratana, PhD, EpiBone, United States, "Translation of Stem Cell-Based Tissue Engineered Medical Products from Research to IND Approvals"
  • Remo Moomiaie-Qajar, MD, Founder and CEO, Cytonus Therapeutics, United States, "Cargocytes a Novel mRNA Therapeutic Platform Beyond the LNP"
As first generation MSC products navigate through late-stage trials and early commercialization in multiple geographies, the GMP supply chain and scalable MSC manufacturing technology have progressed to the point that MSCs can be starting materials or sub-components within next generation therapeutic products, with product development and clinical translation timelines happening at an accelerated pace. This session will highlight leading technology where MSCs are manufacturing starting materials, but the final product is not a simple cell suspension for infusion.

Yes, “live MSCs” are still good for something. 
Jon Rowley
Chief Rooster
 RoosterBio
 Chair
Gihoon Nam
CEO
 SHIFTBIO INC.
 Speaker
Sarindr Bhumiratana
Chief Scientific Officer
 EpiBone Inc
 Speaker
Remo Moomiaie
CEO
 Cytonus Therapeutics, Inc.
 Speaker
< Back to Agenda